share_log

Evercore ISI Group Upgrades Health Catalyst to Outperform, Raises Price Target to $11

Evercore ISI Group Upgrades Health Catalyst to Outperform, Raises Price Target to $11

Evercore ISI集團將健康催化劑上調至跑贏大盤,將目標股價上調至11美元
Benzinga ·  01/03 08:06

Evercore ISI Group analyst Elizabeth Anderson upgrades Health Catalyst (NASDAQ:HCAT) from In-Line to Outperform and raises the price target from $9 to $11.

Evercore ISI集團分析師伊麗莎白·安德森將Health Catalyst(納斯達克股票代碼:HCAT)從In-Line上調至跑贏大盤,並將目標股價從9美元上調至11美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論